JP2023551982A5 - - Google Patents
Info
- Publication number
- JP2023551982A5 JP2023551982A5 JP2023534301A JP2023534301A JP2023551982A5 JP 2023551982 A5 JP2023551982 A5 JP 2023551982A5 JP 2023534301 A JP2023534301 A JP 2023534301A JP 2023534301 A JP2023534301 A JP 2023534301A JP 2023551982 A5 JP2023551982 A5 JP 2023551982A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- sequence encoding
- nucleotide sequence
- promoter
- self
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063120362P | 2020-12-02 | 2020-12-02 | |
| US63/120,362 | 2020-12-02 | ||
| PCT/IB2021/061203 WO2022118226A1 (en) | 2020-12-02 | 2021-12-02 | Multicistronic rna vaccines and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023551982A JP2023551982A (ja) | 2023-12-13 |
| JP2023551982A5 true JP2023551982A5 (enExample) | 2024-11-07 |
Family
ID=81852979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023534301A Pending JP2023551982A (ja) | 2020-12-02 | 2021-12-02 | マルチシストロン性ｒｎａワクチン及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240024455A1 (enExample) |
| EP (1) | EP4255446A4 (enExample) |
| JP (1) | JP2023551982A (enExample) |
| KR (1) | KR20230120646A (enExample) |
| CN (1) | CN117222415A (enExample) |
| AU (1) | AU2021392077A1 (enExample) |
| CA (1) | CA3199996A1 (enExample) |
| IL (1) | IL303315A (enExample) |
| WO (1) | WO2022118226A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023521662A (ja) | 2020-04-03 | 2023-05-25 | グリットストーン バイオ インコーポレイテッド | 感染症抗原及びワクチン |
| US20240009296A1 (en) * | 2022-07-10 | 2024-01-11 | Pfizer Inc. | Self-amplifying rna encoding an influenza virus antigen |
| WO2024033794A1 (en) * | 2022-08-08 | 2024-02-15 | Seqirus Inc. | Rna encoding virus-like particles and uses thereof |
| TW202438672A (zh) * | 2023-01-31 | 2024-10-01 | 美商亞克圖羅斯醫療公司 | 四價流感疫苗之方法及組成物 |
| EP4661903A1 (en) * | 2023-02-09 | 2025-12-17 | Pfizer Inc. | Nucleic acids and uses thereof |
| AU2024271830A1 (en) * | 2023-05-12 | 2025-11-27 | Seqirus Inc. | Vaccine adjuvants |
| AU2024285035A1 (en) * | 2023-06-09 | 2026-01-15 | Rinuagene Biotechnology Co., Ltd. | Expression-adjustable engineered rna molecule |
| WO2024257026A1 (en) * | 2023-06-16 | 2024-12-19 | Seqirus Inc. | Virus-like particles for the treatment of sars-cov2 |
| KR20260074932A (ko) * | 2023-06-30 | 2026-05-27 | 세퀴러스 인코포레이티드 | 복합 rna 백신 |
| CN121752291A (zh) * | 2023-06-30 | 2026-03-27 | 思齐乐私人有限公司 | SARS-CoV-2 RNA疫苗及其用途 |
| AU2025226115A1 (en) * | 2024-02-21 | 2026-07-02 | Seqirus Inc. | Alternative self-amplifying rna |
| WO2025217136A2 (en) * | 2024-04-08 | 2025-10-16 | Amplitude Therapeutics, Inc. | Trans-amplifying rnas encoding immunomodulators |
| WO2025215618A1 (en) * | 2024-04-12 | 2025-10-16 | Seqirus Inc. | Methods and reagents for treating or preventing ebv |
| WO2025230868A1 (en) * | 2024-04-29 | 2025-11-06 | Trustees Of Boston University | Self-amplifying rna and methods |
| WO2025257691A1 (en) * | 2024-06-10 | 2025-12-18 | Seqirus Inc. | Potency assay |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030232324A1 (en) * | 2001-05-31 | 2003-12-18 | Chiron Corporation | Chimeric alphavirus replicon particles |
| US20090104226A1 (en) * | 2004-05-21 | 2009-04-23 | Novartis Vaccines And Diagnostics Inc. | Alphavirus Vectors for Respiratory Pathogen Vaccines |
| EP2451475A2 (en) * | 2009-07-06 | 2012-05-16 | Novartis AG | Self replicating rna molecules and uses thereof |
| US9636410B2 (en) * | 2011-07-06 | 2017-05-02 | Glaxosmithkline Biologicals Sa | Cationic oil-in-water emulsions |
| BR112014008694A2 (pt) * | 2011-10-11 | 2017-06-20 | Novartis Ag | moléculas de ácido nucleico policistrônico recombinante |
| EP3015475A1 (en) * | 2014-10-31 | 2016-05-04 | Novartis AG | Mammalian cells expressing cytomegalovirus antigens |
| WO2017208191A1 (en) * | 2016-06-02 | 2017-12-07 | Glaxosmithkline Biologicals Sa | Zika viral antigen constructs |
| RU2019119272A (ru) * | 2016-11-23 | 2020-12-24 | Гритстоун Онколоджи, Инк. | Вирусная доставка неоантигенов |
| US11339395B2 (en) * | 2018-08-01 | 2022-05-24 | Massachusetts Institute Of Technology | RNA-based regulatory technologies for miRNA sensors |
| AU2019321186B2 (en) * | 2018-08-17 | 2024-05-23 | Glaxosmithkline Biologicals Sa | Immunogenic compositions and uses thereof |
-
2021
- 2021-12-02 AU AU2021392077A patent/AU2021392077A1/en active Pending
- 2021-12-02 EP EP21900187.2A patent/EP4255446A4/en active Pending
- 2021-12-02 KR KR1020237021041A patent/KR20230120646A/ko active Pending
- 2021-12-02 IL IL303315A patent/IL303315A/en unknown
- 2021-12-02 JP JP2023534301A patent/JP2023551982A/ja active Pending
- 2021-12-02 WO PCT/IB2021/061203 patent/WO2022118226A1/en not_active Ceased
- 2021-12-02 US US18/037,226 patent/US20240024455A1/en active Pending
- 2021-12-02 CN CN202180089244.XA patent/CN117222415A/zh active Pending
- 2021-12-02 CA CA3199996A patent/CA3199996A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019210189A1 (en) | Induce and enhance immune responses using recombinant replicon systems | |
| JP2018186815A5 (enExample) | ||
| JP2015522581A5 (enExample) | ||
| JP2017079787A (ja) | 発現系 | |
| JP2013500015A5 (enExample) | ||
| JP2012050450A (ja) | 改良されたアルファウイルスレプリコンおよびヘルパー構築物 | |
| JP2017522907A5 (enExample) | ||
| PL205955B1 (pl) | Układ oparty na minimalnej liczbie plazmidów do wytwarzania infekcyjnych wirusów RNA o ujemnej nici, komórka gospodarza zawierająca taki układ, sposób wytwarzania wiriona wirusa RNA o ujemnej nici, sposób wytwarzania atenuowanego wirusa RNA o ujemnej nici, sposób wytwarzania zakaźnego wirusa o ujemnej nici do stosowania w szczepionkach i zastosowanie układu opartego na minimalnej liczbie plazmidów | |
| JP2008520248A (ja) | タンデム転写ユニットを有する組換えインフルエンザベクター | |
| Schneider-Schaulies et al. | Measles virus in the CNS: the role of viral and host factors for the establishment and maintenance of a persistent infection | |
| JPWO2012053646A1 (ja) | ワクシニアウイルスベクターおよびセンダイウイルスベクターからなるプライム／ブーストワクチン用ウイルスベクター | |
| US12533404B2 (en) | Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases | |
| JP2023521662A5 (enExample) | ||
| JP2025169249A5 (enExample) | ||
| JP2024501085A (ja) | Ｒｎａ構築物 | |
| Kwak et al. | Generation of a recombinant viral hemorrhagic septicemia virus (VHSV) expressing olive flounder (Paralichthys olivaceus) interferon-γ and its effects on type I interferon response and virulence | |
| US11859199B2 (en) | Adenoviral vectors with two expression cassettes encoding RSV antigenic proteins or fragments thereof | |
| Morrow et al. | Recombinant viruses as vectors for mucosal immunity | |
| RU2023112739A (ru) | Мультицистронные РНК-вакцины и их применение | |
| JP2024523329A5 (enExample) | ||
| Zhu et al. | Reverse genetics of rabies virus: new strategies to attenuate virus virulence for vaccine development | |
| EP4082567A1 (en) | Influenza virus vector-based novel coronavirus vaccine and preparation method therefor | |
| US20160279229A9 (en) | Viral Vaccine Vectors | |
| Von Messling et al. | Toward novel vaccines and therapies based on negative-strand RNA viruses | |
| Karlsson et al. | Live viral vectors: Semliki Forest virus |